Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C62791
http://purl.obolibrary.org/obo/NCIT_C62791
Preferred Name

Pegdinetanib
Definitions
A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A pegylated form of a thermostable and protease resistant peptide targeting human vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic activity. Derived from the 10th type III domain of human fibronectin and one of the natural ligands, pegdinetanib binds to VEGFR-2 and prevents activation of VEGFR-2 by other activating ligands. This may inhibit the growth of new tumor blood vessels.
prefLabel
Pegdinetanib
label
Pegdinetanib
PDQ_Closed_Trial_Search_ID
575516
code
C62791
Has_Target
prefixIRI
NCIT:C62791
in_subset
Display_Name
Pegdinetanib
Preferred_Name
Pegdinetanib
FDA_UNII_Code
SSB56T0M0L
Contributing_Source
CTRP
FDA
Maps_To
Pegdinetanib
CAS_Registry
906450-24-6
NCI_Drug_Dictionary_ID
575516
Legacy Concept Name
CT-322
type
ALT_DEFINITION
A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
575516
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C1831965
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display